Introduction {#Sec1}
============

Areal bone mineral density (BMD~a~) as determined by dual-energy X-ray absorptiometry (DXA) is an important determinant of future fracture risk \[[@CR1], [@CR2]\]. However, other factors, including bone size and shape, also influence bone strength and susceptibility to fracture \[[@CR3], [@CR4]\]. Lower bone width, cortical area, and thickness as measured by DXA at both axial and peripheral skeletal sites have been associated with higher risk of fragility fractures \[[@CR5]\]. Quantitative computed tomography (QCT) provides additional information on bone compartments, including volumetric bone mineral density (vBMD) at both predominantly cortical and trabecular sites, and geometric parameters of bone, including area, cortical thickness, and strength \[[@CR6]\]. QCT measurements can be made at both axial and appendicular sites; the forearm is the most common appendicular site. Previous studies have shown that radius vBMD and geometry-based parameters are associated with risk of fracture in both men \[[@CR7]\] and women \[[@CR8]--[@CR11]\].

Genetic factors are known to influence both bone mass and structure. Data from family and twin studies suggest that genetic factors explain about 50% of variation in the total radius and trabecular vBMD and up to 40% of cortical vBMD \[[@CR12], [@CR13]\]. In addition, a large proportion of the variation in geometric parameters such as radius cross-sectional area (27%) and cortical thickness (51%) is attributable to genetic factors \[[@CR13]\].

The RANKL/RANK/OPG signaling pathway has a critical role in bone remodeling. Higher OPG plasma concentration has been associated with higher femoral neck BMD~a~, width, and strength \[[@CR14]\]. Strong evidence of association has previously been found between single-nucleotide polymorphisms (SNPs) within these genes and bone-related phenotypes in both candidate gene studies \[[@CR15]\] and genomewide association studies (GWAS) \[[@CR16]--[@CR19]\]. Despite the critical importance of the RANKL/RANK/OPG signaling pathway, few studies have examined the association between polymorphisms within genes in this pathway and either vBMD or bone geometric parameters. Paternoster et al. \[[@CR20]\] investigated the association between four SNPs near *RANKL*, *RANK*, and *OPG* strongly associated with lumbar spine or hip BMD~a~ in GWAS and tibial peripheral QCT (pQCT) measures (both density and geometry) in young European individuals. They observed significant associations between *OPG* (rs4355801 and rs6993813) and *RANK* (rs3018362) SNPs and cortical vBMD. Recently, a GWAS of pQCT outcomes at the tibia has been published by the same group. In this study, a single SNP (rs1021188) in the vicinity of *RANKL* was associated with lower cortical vBMD at the genomewide significant level and less strongly with geometric parameters. It was also associated with higher plasma levels of soluble RANKL \[[@CR21]\]. Yamada et al. \[[@CR22]\] also examined the association between rs2073617 and rs3134069 in *OPG* and vBMD in the distal and proximal radius in 2,220 Japanese men and women and found significant associations with radial vBMD in women. However, Yerges et al. \[[@CR23], [@CR24]\] found no associations between tagging and potentially functional SNPs in *RANKL*, *RANK*, and *OPG* and vBMD at the femoral neck and lumbar spine in 862 Caucasian men in the Osteoporotic Fractures in Men (MrOS) study.

Here, we used data from the European Male Ageing Study (EMAS), a population-based study of aging, to determine whether SNPs in *RANKL*, *RANK*, and *OPG* are associated with vBMD and bone geometric parameters at the mid-shaft and distal radius in middle-aged and elderly European men.

Materials and Methods {#Sec2}
=====================

Study Participants {#Sec3}
------------------

Men aged 40--79 years were recruited from population registers in European centres, as described before \[[@CR25]\]. Stratified sampling was used, with the target of recruiting equal numbers of men in each of four 10-year age bands (40--49, 50--59, 60--69, and 70--79 years). Subjects were invited to participate by letter, and those who agreed were asked to attend for a more comprehensive assessment including a blood sample for genetic analysis. pQCT was performed in a subsample of subjects in two centers (Manchester, UK, and Leuven, Belgium). Participants were subsequently excluded from the analysis if they reported that at least one of their parents or grandparents was born outside Europe or North America or if they reported use of antiosteoporotic medications or systemic glucocorticoids. Ethical approval in each center was obtained in accordance with local practice and requirements, and subjects gave informed consent.

pQCT {#Sec4}
----

pQCT measurements were performed in the nondominant radius using an XCT-2000 scanner (Stratec, Pforzheim, Germany) in each center following the manufacturer's standard quality-assurance procedures. Total and trabecular vBMD (mg/mm^3^) and bone cross-sectional area (mm^2^) were measured at the distal radius (4%, voxel size 0.4 mm). Cortical vBMD (mg/mm^3^); total, cortical, and medullary area (mm^2^); cortical thickness (mm); and stress strain index (SSI, mm^3^) were measured at the mid-shaft radius (50%, voxel size 0.6 mm). The detailed methodology for these measurements has been described previously \[[@CR26]\].

The European Forearm Phantom (EFP) was measured for cross-calibration between the two centers; 10 repeat measurements were taken in slices 1--4. The differences were less than precision error for total, trabecular, and cortical vBMD and for cortical area; therefore, no cross-calibration was performed between the two centers.

The short-term precision values of two repeat measurements with repositioning were as follows: total vBMD 2.1 and 1.3%; trabecular vBMD 1.27 and 1.42%; cortical vBMD 0.77 and 0.71%; and cortical area 2.4 and 1.3% in Manchester (*n* = 22) and Leuven (*n* = 40), respectively.

Genotype Data {#Sec5}
-------------

Genotype data for pairwise tagging SNPs in *RANKL* (receptor activator of NF-κB ligand, official gene symbol *TNFSF11*) (*n* = 8), *RANK* (receptor activator of NF-κB, official gene symbol *TNFRSF11A*) (*n* = 44), and *OPG* (osteoprotegerin, official gene symbol *TNFRSF11B*) (*n* = 22) and for additional *OPG* (*n* = 3) and *RANKL* (*n* = 2) SNPs associated with BMD~a~ in GWAS were generated in EMAS as previously described. These SNPs were previously tested for association with markers of bone turnover, calcaneal quantitative ultrasound parameters, and BMD~a~ at the lumbar spine and total hip as measured by DXA in this cohort \[[@CR15]\].

Statistical Analysis {#Sec6}
--------------------

Linear regression under an additive genetic model was used to test for association between SNPs and the outcome variables, adjusting for center using PLINK (1.05) \[[@CR27]\]. Significant results were further adjusted for age, weight, and height. The results are reported as the change in the mean of the outcome variable (β coefficient) for each copy of the minor allele with 95% confidence intervals (CIs). For significant associations, the interaction between SNP and center was tested to determine if there was any between-center heterogeneity using STATA (9.2; StataCorp LP, 4905 Lakeway Drive, College Station, TX).

Assuming a 0.05 type I error, minor allele frequencies (MAFs) of 0.05--0.45, and 588 individuals, this study had \>80% power to detect differences of at least 0.4 SD (MAF = 0.05) and 0.2 SD (MAF = 0.45) for all outcomes under an additive genetic model. The power of the study was also calculated assuming a more conservative type I error of 0.0008 to take into account multiple testing, which was calculated by dividing 0.05 by the number of independent genotyped SNPs according to the method described by Li and Ji \[[@CR28]\]. With a 0.0008 type I error, the study had \>80% power to detect differences of at least 0.4 SD (MAF = 0.05) and 0.3 SD (MAF = 0.45) for all outcomes. Statistical power was calculated using Quanto v1.2.3 software \[[@CR29]\].

Results {#Sec7}
=======

Subject Characteristics {#Sec8}
-----------------------

In total, 589 men, mean (± SD) age 60 (± 11) years, were included in the analysis. Characteristics of the pQCT parameters are presented in Table [1](#Tab1){ref-type="table"}.Table 1pQCT parameters: mean and standard deviation (SD)Variable*n*MeanSDDistal radius Total vBMD (mg/mm^3^)588399.671.9 Trabecular vBMD (mg/mm^3^)588203.643.0 Cross-sectional area (mm^2^)588376.066.7Midshaft radius Cortical vBMD (mg/mm^3^)5891,214.630.2 Cortical thickness (mm)5893.20.4 Total area (mm^2^)589149.621.7 Cortical area (mm^2^)589106.413.8 Medullary area (mm^2^)58943.217.6 SSI (mm^3^)589337.665.1

Genetic Association Analysis {#Sec9}
----------------------------

### RANKL {#Sec10}

We identified four *RANKL* tag SNPs (rs346588, rs9562414, rs633137, and rs346574) associated with greater medullary area at the mid-shaft radius. However, none of these associations remained significant after adjustment for age, weight, and height (Supplementary Table 1).

There was no association between the two SNPs near *RANKL* selected from GWAS (rs9594738 and rs9594759) and pQCT outcomes.

### RANK {#Sec11}

We identified three *RANK* SNPs associated with vBMD: rs9962159 associated with lower total vBMD, rs12956925 and rs4524035 associated with lower trabecular vBMD at the distal radius. Four *RANK* SNPs (rs9951012, rs8083511, rs6567276, and rs17665435) were associated with the distal radius cross-sectional area. A single SNP, rs12959396, was associated with both higher cortical thickness and smaller medullary area at the mid-shaft radius, but the association with medullary area did not remain significant after adjustment for age, weight, and height (Table [2](#Tab2){ref-type="table"}). Only modest linkage disequilibrium (LD) exists between the associated SNPs, *r*^2^ ≤ 0.36.Table 2*RANK* (*TNFRSF11A*) SNPs associated with pQCT outcomesSNPAlleleMAF (%)TypeSkeletal sitePhenotypeAdjusted for centerAdjusted for center, age, weight, and heightAssociations with other bone phenotypes in EMAS \[[@CR15]\]^a^β (95% CI)*P*β (95% CI)*P*rs9962159A\>G27.5IntronicDistal radiusTotal vBMD−8.33 (−16.29 to −0.38)0.041−8.55 (−16.16 to −0.93)0.028--rs12956925G\>A16.7IntronicDistal radiusTrabecular vBMD−6.79 (−13.22 to −0.36)0.039−7.58 (−14.01 to −1.15)0.021--rs9951012G\>A20.8IntronicDistal radiusCross-sectional area−9.28 (−17.87 to −0.69)0.035−10.23 (−18. 42 to −2.03)0.015--rs4524035A\>G14.3IntronicDistal radiusTrabecular vBMD−8.59 (−16.30 to −0.87)0.030−8.35 (−16.09 to −0.60)0.035--rs8083511A\>C20.1IntronicDistal radiusCross-sectional area10.39 (2.05 to 18.73)0.0158.90 (0.92 to 16.88)0.029--rs12959396T\>G47.1IntronicMid-shaft radiusCortical thickness0.05 (0.00 to 0.10)0.0460.06 (0.01 to 0.10)0.026--Mid-shaft radiusMedullary area−2.31 (−4.36 to −0.26)0.028−1.87 (−3.85 to 0.12)0.065--rs6567276T\>C44.2IntronicDistal radiusCross-sectional area−7.50 (−14.35 to −0.65)0.032−8.42 (−14.97 to −1.87)0.012**PINP ↑**, CTX-I ↑rs17665435T\>A32.33′ downstreamDistal radiusCross-sectional area7.44 (0.52 to 14.36)0.0368.21 (1.58 to 14.83)0.015PINP ↓, CTX-I ↓*β* the change in the mean of the outcome variable (in units e.g. mg/mm^3^) for each copy of the minor allele, *CI* confidence interval, *EMAS* European Male Ageing Study, *PINP* N-terminal propeptide of procollagen I, *CTX-I* C-terminal cross-linked telopeptide of collagen type I, ↑ the SNP was associated with higher levels of the outcome, ↓ the SNP was associated with lower levels of the outcome^a^Outcomes shown in bold were also significantly associated with the SNP in the subpopulation with pQCT

There was no evidence of heterogeneity between centers for SNP associations with pQCT parameters as tested by SNP center interaction analysis.

In order to account for the number of independent SNPs tested (*n* = 62), which was calculated by the method described by Li and Ji \[[@CR28]\], SNP associations would need to reach a *P* value of \<0.0008 to achieve statistical significance. None of the SNPs reached this level of significance.

### OPG {#Sec12}

We identified seven tag SNPs in *OPG* associated with total and/or cortical vBMD: rs3134058 and rs3102724 associated with lower total vBMD at the distal radius; rs2073618, rs3134057, and rs1032129 associated with lower cortical vBMD at the mid-shaft radius; and rs10505348 and rs2073617 associated with both total and cortical vBMD (Table [3](#Tab3){ref-type="table"}). There was a moderate to high LD (*r*^2^ \> 0.50) between most of these SNPs (Fig. [1](#Fig1){ref-type="fig"}). The SNPs rs2073618 and rs3134058 (*r*^2^ = 0.75) were also associated with lower cortical thickness, and rs10505348 was associated with both higher cortical thickness and smaller medullary area at the mid-shaft radius. The tag SNP rs1032128 was only associated with lower cortical thickness at the mid-shaft radius. We also identified two tag SNPs in *OPG*, rs3102735 and rs4876868 (*r*^2^ = 0.65), associated with higher SSI; but the association between rs3102735 and SSI did not remain significant after adjustment for age, weight, and height (Table [3](#Tab3){ref-type="table"}).Table 3*OPG* (*TNFRSF11B*) SNPs associated with pQCT outcomesSNPAlleleMAF (%)TypeSkeletal sitePhenotypeAdjusted for centerAdjusted for center, age, weight, and heightAssociations with the other bone phenotypes in EMAS \[[@CR15]\]^a^β (95% CI)*P*β (95% CI)*P*rs6993813C\>T45.95′ upstreamMid-shaft radiusCortical vBMD4.29 (0.72 to 7.86)0.0193.93 (0.47 to 7.39)0.026**PINP ↓**, **CTX-I ↓**rs6469804A\>G43.95′ upstreamMid-shaft radiusCortical vBMD4.36 (0.76 to 7.95)0.0184.25 (0.76 to 7.73)0.017**PINP ↓, CTX-I ↓**rs10505348C\>T44.55′ upstreamDistal radiusTotal vBMD7.89 (0.34 to 15.44)0.0419.35 (2.12 to 16.58)0.011**PINP ↓, CTX-I ↓**Mid-shaft radiusCortical vBMD5.69 (2.08 to 9.31)0.0025.62 (2.10 to 9.14)0.002--Mid-shaft radiusCortical thickness0.06 (0.01 to 0.11)0.0260.08 (0.03 to 0.13)0.002--Mid-shaft radiusMedullary area−2.33 (−4.45 to −0.21)0.031−2.90 (−4.94 to −0.86)0.005--rs3102735T\>C14.55′ upstreamMid-shaft radiusSSI11.23 (0.95 to 21.51)0.0338.83 (−0.96 to 18.61)0.077--rs2073617G\>A49.35′ UTRDistal radiusTotal vBMD−9.00 (−16.27 to −1.73)0.016−9.82 (−16.76 to −2.88)0.006CTX-I ↑Mid-shaft radiusCortical vBMD−4.95 (−8.44 to −1.45)0.006−4.87 (−8.26 to −1.48)0.005--rs2073618G\>C47.3NonsynonymousMid-shaft radiusCortical vBMD−3.78 (−7.38 to −0.18)0.040−4.30 (−7.78 to −0.82)0.015**PINP ↑**, **CTX-I ↑**Lys\>AspMid-shaft radiusCortical thickness−0.07 (−0.12 to −0.01)0.012−0.08 (−0.13 to −0.03)0.001**LS BMD**~**a**~**↓**rs3134058G\>A40.8IntronicDistal radiusTotal vBMD−7.58 (−14.87 to −0.29)0.042−9.61 (−16.55 to −2.66)0.007CTX-I ↑, **LS BMD**~**a**~**↓**Mid-shaft radiusCortical thickness−0.05 (−0.10 to 0.00)0.046−0.06 (−0.11 to 0.01)0.014--rs3134057A\>G38.9IntronicMid-shaft radiusCortical vBMD−3.77 (−7.37 to −0.17)0.041−4.21 (−7.70 to −0.73)0.018**CTX-I ↑**, **LS BMD**~**a**~**↓**rs1032129A\>C34.8IntronicMid-shaft radiusCortical vBMD−4.65 (−8.33 to −0.98)0.013−4.20 (−7.77 to −0.63)0.021--rs1032128G\>A27.3IntronicMid-shaft radiusCortical thickness−0.06 (−0.12 to −0.01)0.033−0.07 (−0.12 to −0.01)0.016PINP ↑rs3102724G\>A35.1IntronicDistal radiusTotal vBMD−8.00 (−15.65 to −0.35)0.041−10.36 (−17.65 to −3.07)0.005CTX-I ↑, **LS BMD**~**a**~**↓**rs4876868G\>A17.33′ downstreamMid-shaft radiusSSI12.20 (2.18 to 22.22)0.01712.48 (3.02 to 21.95)0.010CTX-I ↑rs4355801A\>G46.23′ downstreamMid-shaft radiusCortical vBMD5.39 (1.76 to 9.02)0.0045.05 (1.51 to 8.59)0.005PINP ↓, **CTX-I ↓**Mid-shaft radiusSSI−8.64 (−16.47 to −0.81)0.031−8.38 (−15.74 to −1.01)0.026--*β* change in the mean of the outcome variable (in units, mg/mm^3^) for each copy of the minor allele, *UTR* untranslated region, *LS* lumbar spine, ↑ SNP was associated with higher levels of the outcome, ↓ SNP was associated with lower levels of the outcome^a^Outcomes shown in bold were also significantly associated with the SNP in the subpopulation with pQCTFig. 1The LD pattern between *OPG* (*TNFRSF11B*) SNPs associated with pQCT outcomes. SNP positions within the gene and pairwise LD (*blackr*^2^ = 1, *whiter*^2^ = 0) are shown

All three SNPs near *OPG* selected from GWAS (rs4355801, rs6469804, and rs6993813) were associated with higher cortical vBMD at the mid-shaft radius, and rs4355801 was also associated with SSI (Table [3](#Tab3){ref-type="table"}). No significant association was observed between these SNPs and the other pQCT outcomes.

There was no evidence of heterogeneity between centers for SNP associations with pQCT parameters as tested by SNP center interaction analysis.

None of the SNPs reached the level of significance required to correct for multiple testing (*P* \< 0.0008).

Discussion {#Sec13}
==========

To our knowledge, this study is the first in which SNPs within *RANKL*, *RANK*, and *OPG* have been tested for association with bone vBMD and geometric parameters measured by pQCT with good gene coverage. These results are complementary to our previous analysis, which suggested that SNPs within *RANKL*, *RANK*, and *OPG* influence bone turnover and BMD~a~ in this population of men \[[@CR15]\].

We found multiple SNPs in *RANK* and *OPG* associated with radius geometry or vBMD (cortical, trabecular, and total), with some SNPs associating with both. Some of these SNPs were also associated with bone turnover and BMD~a~ in our previous study \[[@CR15]\].

Multiple SNPs in *RANK* in low LD were associated with total or trabecular vBMD or radius geometric parameters. Two SNPs, rs6567276 and rs17665435, which were associated with distal radius cross-sectional area, were also associated with serum levels of N-terminal propeptide of procollagen I (PINP) and C-terminal cross-linked telopeptide of collagen type I (CTX-I) bone turnover markers in this population, as reported previously \[[@CR15]\]. The association between rs6567276 and PINP was still significant in the pQCT subpopulation. The effect on distal radius cross-sectional area was in the opposite direction to their effect on bone turnover markers \[[@CR15]\] (Table [3](#Tab3){ref-type="table"}).

Eight tag SNPs in *OPG* were associated with vBMD and/or cortical thickness, with some SNPs associating with both and in the same direction; e.g., rs10505348 was associated with higher vBMD (both total 4% site and cortical 50% site) and cortical thickness. Some of the *OPG* SNPs associated here with vBMD have previously been associated with lumbar spine BMD~a~ (with the same direction of effect) in a large GWAS meta-analysis at the genomewide significant level (rs10505348, rs2073617, and rs2073618) \[[@CR17]\] and in this population as reported previously \[[@CR15]\] (Table [3](#Tab3){ref-type="table"}). Furthermore, rs2073617 \[[@CR30], [@CR31]\], rs2073618 \[[@CR31]--[@CR38]\], and rs1032129 \[[@CR39]\] have previously been reported in association with lower BMD~a~ measured by DXA at different skeletal sites. As QCT measures of BMD are not confounded by bone size, this provides evidence that associations seen previously in *OPG* are truly related to density. The SNP rs2073617 has also been reported in association with lower vBMD measured by pQCT at the proximal radius in Japanese premenopausal women \[[@CR22]\]. Most of the SNPs associated with vBMD and/or cortical thickness in our current study were also associated with bone turnover markers in this population, as previously reported \[[@CR15]\]. A number of these associations remained significant when the analysis was limited to the subpopulation with pQCT. A lack of association with PINP or CTX-I in the subpopulation may be due to the reduced statistical power in the subpopulation; however, the effects of SNPs on bone turnover were in the opposite direction to their effects on vBMD and cortical thickness \[[@CR15]\] (Table [3](#Tab3){ref-type="table"}).

The association between SNPs within OPG and serum levels of OPG and soluble RANKL have been investigated in a few studies \[[@CR34], [@CR37], [@CR40]\]. Jorgensen et al. \[[@CR40]\] did not observe any significant association between rs3102735, which was associated with SSI in EMAS, and serum OPG levels. Kim et al. \[[@CR37]\] also did not observe any significant association between rs3102735 and rs2073618 and between serum OPG and soluble RANKL. However, in the Zhao et al. study \[[@CR34]\], the Asn-Asn genotype of rs2073618 was associated with lower serum OPG levels compared to the Lys-Lys genotype. This is consistent with our findings in which the C allele (Asn) was associated with higher bone turnover markers, lower BMD, and lower cortical thickness. OPG acts as a decoy receptor and blocks RANKL effects. RANKL increases the production, activity, and survival of osteoclasts \[[@CR41]\]. Therefore, SNPs that decrease the activity of OPG would be expected to have a negative impact on bone health due to increased resorption.

All three SNPs near *OPG* selected from GWAS were associated with higher cortical vBMD at the mid-shaft radius. In a recent study of young (between 15 and 20 years) European individuals (1,492 males and 1,621 females from the Avon Longitudinal Study of Patents and Children \[ALSPAC\] and 935 males from the Gothenburg Osteoporosis and Obesity Determinants \[GOOD\] study), rs6993813 and rs4355801 were associated with higher cortical vBMD at the tibia \[[@CR20]\].

Our findings contrast with those of Yerges et al. \[[@CR23]\], who investigated SNPs in *RANKL*, *RANK*, and *OPG* and femoral neck (total, cortical, and trabecular) and lumbar spine (total) vBMD. They did not observe any significant association between *RANKL*, *RANK*, and *OPG* SNPs and vBMD (total, cortical, or trabecular). The apparent discrepant findings may relate to different sites of assessment. In addition, their gene coverage for SNPs with MAF \> 5% ranged from 1 to 100% per gene (64% on average); therefore, they might not have genotyped the associating SNPs \[[@CR23], [@CR24]\]. Our gene coverage for SNPs with MAF \> 5% was \>98%.

EMAS is a multicenter, population-based study; and standard methods were used to minimize any variation between centers. However, it has some limitations which should be considered. As the response rate was about 39%, those who declined to participate may have differed from those who agreed to participate. Therefore, caution is needed in interpreting the results, such as absolute values of the phenotype data. However, considering that the main analysis was based on a within-cohort analysis, it is unlikely that the main findings would be influenced by any selection factors. False results might be produced due to population substructure. There was no evidence of any between-center heterogeneity, and the likelihood of population stratification was minimized by excluding subjects of non-European ancestry. However, we were unable to use methods such as genomic control or principal component analysis to determine if there was any population substructure as these methods need data on a large number of SNPs. False-positive associations might be detected due to multiple testing, whereas genuine associations might be missed due to power constraints. Based on the method described by Li and Ji \[[@CR28]\], there were 62 independent SNPs in *RANKL* (*n* = 8), *RANK* (*n* = 36), and *OPG* (*n* = 18). Using Bonferroni correction to correct for multiple testing, the new cut-off for the *P* value will be 0.0008 (0.05/62 = 0.0008). None of the associations we found here reached this level of significance. Some of the SNPs (i.e., in *OPG*) associated with radius vBMD in the present study have, however, previously been associated with lumbar spine BMD~a~ in large-scale GWASs. A technical limitation of pQCT measurement of cortical vBMD is the influence of the partial volume effect, which is due to the limited spatial resolution of pQCT. Therefore, some of the associations with cortical vBMD may be in part due to technical constraints: the thinner the cortices, the lower vBMD. We tried to minimize technical artifacts by using a higher threshold for analysis of cortical vBMD (960 mg/cm^3^) rather than the traditional 710 mg/cm^3^ \[[@CR42]\], to try to reduce the partial volume effect.

To summarize, these findings add to our knowledge of the possible influence of genetic variation in the RANKL/RANK/OPG signaling pathway on bone and suggest that SNPs in *OPG* and *RANK* affect radius vBMD and geometry, especially cortical thickness, in men. The association of *OPG* is more convincing as the results are consistent with previous findings and SNPs are often associated with multiple bone-related phenotypes. However, these findings need to be validated in independent populations. If they are confirmed, fine mapping and functional studies will be needed to identify the causal variants.
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